

# ISPOR 37<sup>th</sup> HTA Roundtable [Europe]

Sunday, 5 November 2017 -- 08:30 - 15:00 Scottish Event Campus (SEC) (Room: Gallery Bistro) Glasgow, Scotland

<u>Co-Chairs:</u> **Wim Goettsch, PhD, MSc** Director **EUnetHTA JA3 Directorate, Zorginstituut Nederland (ZIN)** Diemen, Netherlands

László Nagyjánosi, MSc Head, Health Technology Assessment Division National Institute of Pharmacy and Nutrition (OGYÉI) Budapest, Hungary

<u>HTA Council Chair:</u> **Professor Finn Børlum Kristensen, MD, PhD** Former EUnetHTA Executive Committee Chairman and EUnetHTA Secretariat Director Professor, Faculty of Health Sciences, **University of Southern Denmark** Hillerød, Denmark

European Commission Flora Giorgio Policy Officer, DG Sanco European Commission Brussels, Belgium

<u>World Health Organization</u> Sarah Garner, PhD, BPharm Coordinator, Innovation, Access and Use, Essential Medicines and Health Products World Health Organization Geneva, Switzerland

<u>Austria</u> **Gottfried Endel, MD** Head of Department for Evidence Based Economic Health Care **Main Association of Austrian Social Security Institutions** Vienna, Austria

Katharina Hawlik, MD, MSc Project Lead, Medical Devices Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) Vienna, Austria

Ingrid Rosian-Schikuta, Mag. Deputy Head, Health Economics Department Gesundheit Österreich GmbH (GÖG) Vienna, Austria



Belgium Francis Arickx Head, Directorate Pharmaceutical Policy National Institute for Health and Disability Insurance (RIZIV INAMI) Brussels, Belgium

Dr. Raf Mertens General Manager Federal Centre for Health Care Knowledge (KCE) Brussels, Belgium

Bosnia and Herzegovina Vladimir Guzvic, MD, PhD Medical Doctor, Department of Clinical Pharmacology Health Insurance Fund Banja Luka, Bosnia and Herzegovina

<u>Croatia</u> **Mirjana Huić, MD, PhD** Clinical Pharmacologist and Toxicologist Assistant Director, Department for Development, Research and Health Technology Assessment **Agency for Quality and Accreditation in Health Care and Social Welfare** Zagreb, Croatia

Mirela Pučić, mag.math Coordinator for Economic Affairs Croatian Institute for Health Insurance Zagreb, Croatia

<u>Czech Republic</u> **Milan Vocelka, MSc** Health Economist, HTA Department **State Institute for Drug Control (SÚKL)** Prague, Czech Republic

Denmark Asger Lindvig Health Economist AMGROS Copenhagen, Denmark

Camilla Nielsen, PhD, MSc Research Director, Health Technology Assessment & Health Services Research DEFACTUM Aarhus, Denmark

<u>Finland</u> **Piia Rannanheimo, MSc** Pharmacoeconomist **Finnish Medicines Agency (FIMEA)** Kuopio, Finland



<u>François Meyer, MD</u> Advisor to the President, International Affairs Director, Health Technology Assessment Division Haute Autorité de Santé (HAS) Saint-Denis La Plaine, France

<u>Germany</u> Alric Rüther, MD, PhD Head, International Affairs Institute for Quality and Efficiency in Health Care (IQWiG) Cologne, Germany

Susanne Brück Scientific Advisor, Pharmaceuticals Department Gemeinsamer Bundesausschuss (G-BA, Federal Joint Committee) Berlin, Germany

Ireland Michael Barry, MD, PhD, FRCPI Clinical Director, National Centre for Pharmacoeconomics St. James's Hospital Dublin, Ireland

Conor Teljeur, PhD Chief Scientist, HTA Health Information and Quality Authority (HIQA) Dublin, Ireland

<u>Kazakhstan</u> Alima Almadiyeva, MD, MSc Chief Scientific and Operations Officer Kazakh Agency for Health Technology Assessment (HTA) Astana, Kazakhstan

Professor Alexander Kostyuk, MD, PhD Head, Center of Excellence, Republican Healthcare Development Center Ministry of Health and Social Development of Republic of Kazakhstan Astana, Kazakhstan

<u>The Netherlands</u> **Saskia Knies, PhD, MPhil** Pharmacoeconomics Advisor **Zorginstituut Nederland (ZIN)** Diemen, The Netherlands

<u>Norway</u>

**Øyvind Melien, MD, PhD, MSc** Specialist in Clinical Pharmacology Chair of Secretariat, Norwegian National System for Managed Introduction of Health Technologies Specialist Health Services, Dept. of Medical Devices and Medicinal Products **Norwegian Directorate of Health** Oslo, Norway



Ingvil Sæterdal, PhD, MSc Senior Researcher Norwegian Institute of Public Health Oslo, Norway

Poland Dominik Dziurda, MPH, MBA Director, Healthcare Service Division Agency for Health Technology Assessment and Tariff System (AOTMiT) Warsaw, Poland

Portugal Rui Santos Ivo, PharmD Vice President INFARMED Lisbon, Portugal

Romania Silvia Gabriela Scintee, MD, PhD, MSc Deputy General Director National School of Public Health Bucharest, Romania

Russian Federation George Khachatryan, MD Deputy Director, Department of Comprehensive Health Technology Assessment, FSBI "Center of Healthcare Quality Assessment and Control" Ministry of Health of the Russian Federation Moscow, Russia

Professor Vitaly Omelyanovskiy, MD, PhD, DSc General Director, Department of Comprehensive Health Technology Assessment, FSBI Center of Expertise and Quality Control of Medicines, Ministry of Health of the Russian Federation Head, Financial Scientific Research Institute, Ministry of Finance of the Russian Federation Head, Center for Health Technology Assessment, Russian Presidential Academy of National Economy and Public Administration Moscow, Russia

<u>Slovakia</u> **Tomas Tesar, PharmD, PhD, MBA** Member, Reimbursement Committee **Union Health Insurance Fund** Bratislava, Slovakia

<u>Slovenia</u> Jure Mikolič, MA Pharm Pharmacy Manager, Department of Medicine Health Insurance Institute Slovenia Ljubljana, Slovenia



<u>Spain</u> **Iñaki Imaz-Iglesia, MD, PhD** Senior Researcher **Instituto de Salud Carlos III (AETS-ISCIII)** Madrid, Spain

<u>Sweden</u> Jonas Lindblom, PhD Medical Investigator TLV, The Dental and Pharmaceutical Benefits Agency Stockholm, Sweden

Sophie Werkö, PhD, MSc Project Director, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Vice Chair, International Network of Agencies for Health Technology Assessment (INAHTA) Stockholm, Sweden

<u>Switzerland</u> Goedele van Haasteren, PhD Federal Department of Home Affairs Swiss Federal Office of Public Health Berne, Switzerland

<u>Turkey</u> **Rabia Kahveci, MD, MScHTA** Professor, **Ankara Numune Hospital** Chair, **ANHTA (Ankara Numune HTA Unit)** Consultant, HTA Unit, **Ministry of Health (Agency for Pharmaceuticals and Medical Devices)** Director, **HTAi Ankara, Turkey** 

<u>Ukraine</u>

### Oresta Piniazhko, PhD, PharmD

Assistant Professor, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Postgraduate Faculty, **Danylo Halytsky Lviv National Medical University** Member of Expert Committee, **Ministry of Health of Ukraine** Lviv, Ukraine

United Kingdom

Meindert Boysen, MSc Program Director, Technology Appraisals National Institute for Health and Clinical Excellence (NICE) Manchester, England, United Kingdom

Mirella Marlow, MBA, MA

Program Director, Devices and Diagnostic Systems, Centre for Health Technology Evaluation National Institute for Health and Care Excellence (NICE) London, England, United Kingdom

Anne Lee Chief Pharmacist Scottish Medicines Consortium (SMC) Glasgow, Scotland



## HTA Council members:

<u>Asia-Pacific</u> Sukyeong Kim, PhD Director, Coordinating Center for National Health Clinical Research National Evidence-Based Healthcare Collaborating Agency (NECA) Seoul, South Korea

<u>North America:</u> **Karen Worley, PhD** Research Leader, Comprehensive Health Insights **Humana, Inc.** Cincinnati, OH, USA

Observers from the Middle East and North Africa Ola Ghaleb A. Al Ahdab, PhD, RPh, BSc Pharmaceutical Advisor, Registration and Drug Control Department Ministry of Health

Abu Dhabi, United Arab Emirates

### Professor Ibrahim Allabbadi, PhD, RPh, MBA

Professor, Faculty of Pharmacy **The University of Jordan** Amman, Jordan

#### Abdulaziz Al-Saggabi, PharmD, MSc, BSc

Director, Drug Policy & Economics Center **Ministry of National Guard Health Affairs** Riyadh, Saudi Arabia

### Randa Eldessouki, MBBCh, MSc, MD

Associate Professor, Public Health, **Fayoum University** Member of National Pharmacoeconomic Committee, **Ministry of Health** Cairo, Egypt

Mirna Matni, PharmD Drug Reimbursement, Medical Control Department National Social Security Fund Beirut, Lebanon

Mouna Jameleddine, PharmD, MSc Head, Health Technology Assessment Department National Instance for Assessment & Accreditation in Healthcare (INASanté) Tunis, Tunisia

ISPOR Staff Nancy Berg, CEO & Executive Director Richard Willke, PhD, Chief Science Officer Nadia Naaman, Senior Director, Scientific & Health Policy Initiatives Julia Chamova, MBA, Director, Global Networks - Europe, Middle East, and Africa (EMEA) Kelly Lenahan, Manager, Scientific & Health Policy Initiatives